Boston Scientific Corp Stock Working Capital

BSX Stock

USD 90.00 1.50 1.64%

Boston Scientific Corp fundamentals help investors to digest information that contributes to Boston Scientific's financial success or failures. It also enables traders to predict the movement of Boston Stock. The fundamental analysis module provides a way to measure Boston Scientific's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Boston Scientific stock.

	Last Reported	Projected for Next Year
Net Working Capital	1.6 B	838.8 M
Change In Working Capital	-770 M	-731.5 M

Net Working Capital is likely to drop to about 838.8 M in 2024. Change In Working Capital is likely to rise to about (731.5 M) in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Boston Scientific Corp Company Working Capital Analysis

Boston Scientific's Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .

Working Capital

Current Assets

-

Current Liabilities

More About Working Capital | All Equity Analysis

Current Boston Scientific Working Capital

1.58 B

Most of Boston Scientific's fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Boston Scientific Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Boston Working Capital Driver Correlations

Understanding the fundamental principles of building solid financial models for Boston Scientific is extremely important. It helps to project a fair market value of Boston Stock properly, considering its historical fundamentals such as Working Capital. Since Boston Scientific's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Boston Scientific's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Boston Scientific's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Short Term Investments	Common Stock	Long Term Debt	Good Will	Treasury Stock	Property Plant Equipment	Current Deferred Revenue	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Long Term Investments	Short Long Term Debt	Cash And Equivalents	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.97	0.94	0.5	0.89	0.94	0.77	0.83	0.1	0.59	0.78	0.66	0.87	0.9	-0.75	0.83	-0.45	0.77	0.69	0.79	-0.59	0.66	-0.03	0.66	0.87	0.8	0.7
Total Stockholder Equity	0.97		0.87	0.65	0.9	0.88	0.65	0.78	0.01	0.43	0.77	0.53	0.82	0.89	-0.65	0.81	-0.37	0.85	0.74	0.83	-0.49	0.6	-0.1	0.7	0.91	0.84	0.78
Net Debt	0.94	0.87		0.41	0.83	0.93	0.82	0.79	0.32	0.64	0.84	0.65	0.87	0.82	-0.78	0.77	-0.55	0.64	0.69	0.69	-0.66	0.74	0.17	0.51	0.82	0.71	0.56
Retained Earnings	0.5	0.65	0.41		0.59	0.3	0.05	0.3	-0.13	-0.31	0.57	-0.23	0.4	0.46	-0.12	0.4	-0.18	0.71	0.78	0.66	-0.07	0.36	-0.16	0.6	0.79	0.72	0.69
Accounts Payable	0.89	0.9	0.83	0.59		0.89	0.58	0.7	0.12	0.3	0.85	0.52	0.72	0.79	-0.74	0.78	-0.52	0.82	0.69	0.85	-0.67	0.58	-0.02	0.64	0.86	0.77	0.8
Net Receivables	0.94	0.88	0.93	0.3	0.89		0.76	0.73	0.27	0.67	0.77	0.75	0.76	0.83	-0.76	0.8	-0.46	0.67	0.52	0.7	-0.7	0.57	0.14	0.43	0.73	0.6	0.64
Total Liab	0.77	0.65	0.82	0.05	0.58	0.76		0.92	0.25	0.84	0.59	0.85	0.9	0.83	-0.78	0.82	-0.56	0.35	0.55	0.58	-0.58	0.62	0.09	0.48	0.6	0.58	0.29
Total Current Assets	0.83	0.78	0.79	0.3	0.7	0.73	0.92		0.1	0.62	0.68	0.75	0.93	0.89	-0.82	0.89	-0.54	0.59	0.72	0.8	-0.58	0.71	-0.06	0.75	0.77	0.81	0.53
Short Term Debt	0.1	0.01	0.32	-0.13	0.12	0.27	0.25	0.1		0.28	0.51	0.13	-0.01	0.08	-0.17	0.09	-0.23	-0.18	-0.11	-0.03	-0.28	0.22	0.97	-0.24	0.02	-0.12	-0.1
Intangible Assets	0.59	0.43	0.64	-0.31	0.3	0.67	0.84	0.62	0.28		0.27	0.86	0.61	0.61	-0.52	0.55	-0.29	0.05	0.1	0.18	-0.38	0.3	0.19	0.07	0.22	0.16	0.01
Short Term Investments	0.78	0.77	0.84	0.57	0.85	0.77	0.59	0.68	0.51	0.27		0.37	0.66	0.68	-0.68	0.66	-0.62	0.66	0.67	0.73	-0.66	0.77	0.38	0.58	0.81	0.74	0.61
Common Stock	0.66	0.53	0.65	-0.23	0.52	0.75	0.85	0.75	0.13	0.86	0.37		0.68	0.7	-0.73	0.72	-0.45	0.3	0.25	0.47	-0.63	0.42	-0.02	0.28	0.34	0.33	0.3
Long Term Debt	0.87	0.82	0.87	0.4	0.72	0.76	0.9	0.93	-0.01	0.61	0.66	0.68		0.88	-0.79	0.85	-0.58	0.61	0.83	0.76	-0.57	0.73	-0.17	0.72	0.84	0.83	0.51
Good Will	0.9	0.89	0.82	0.46	0.79	0.83	0.83	0.89	0.08	0.61	0.68	0.7	0.88		-0.64	0.95	-0.42	0.66	0.72	0.82	-0.47	0.54	-0.04	0.63	0.81	0.75	0.64
Treasury Stock	-0.75	-0.65	-0.78	-0.12	-0.74	-0.76	-0.78	-0.82	-0.17	-0.52	-0.68	-0.73	-0.79	-0.64		-0.69	0.58	-0.55	-0.54	-0.66	0.84	-0.72	0.03	-0.61	-0.65	-0.68	-0.45
Property Plant Equipment	0.83	0.81	0.77	0.4	0.78	0.8	0.82	0.89	0.09	0.55	0.66	0.72	0.85	0.95	-0.69		-0.45	0.68	0.72	0.87	-0.54	0.5	-0.04	0.56	0.79	0.72	0.68
Current Deferred Revenue	-0.45	-0.37	-0.55	-0.18	-0.52	-0.46	-0.56	-0.54	-0.23	-0.29	-0.62	-0.45	-0.58	-0.42	0.58	-0.45		-0.27	-0.48	-0.4	0.71	-0.64	-0.11	-0.41	-0.47	-0.49	-0.17
Net Tangible Assets	0.77	0.85	0.64	0.71	0.82	0.67	0.35	0.59	-0.18	0.05	0.66	0.3	0.61	0.66	-0.55	0.68	-0.27		0.71	0.85	-0.45	0.57	-0.27	0.65	0.83	0.82	0.87
Long Term Debt Total	0.69	0.74	0.69	0.78	0.69	0.52	0.55	0.72	-0.11	0.1	0.67	0.25	0.83	0.72	-0.54	0.72	-0.48	0.71		0.85	-0.38	0.68	-0.24	0.76	0.92	0.89	0.68
Capital Surpluse	0.79	0.83	0.69	0.66	0.85	0.7	0.58	0.8	-0.03	0.18	0.73	0.47	0.76	0.82	-0.66	0.87	-0.4	0.85	0.85		-0.54	0.59	-0.16	0.76	0.89	0.86	0.91
Deferred Long Term Liab	-0.59	-0.49	-0.66	-0.07	-0.67	-0.7	-0.58	-0.58	-0.28	-0.38	-0.66	-0.63	-0.57	-0.47	0.84	-0.54	0.71	-0.45	-0.38	-0.54		-0.62	-0.13	-0.37	-0.49	-0.46	-0.41
Long Term Investments	0.66	0.6	0.74	0.36	0.58	0.57	0.62	0.71	0.22	0.3	0.77	0.42	0.73	0.54	-0.72	0.5	-0.64	0.57	0.68	0.59	-0.62		0.06	0.65	0.67	0.75	0.41
Short Long Term Debt	-0.03	-0.1	0.17	-0.16	-0.02	0.14	0.09	-0.06	0.97	0.19	0.38	-0.02	-0.17	-0.04	0.03	-0.04	-0.11	-0.27	-0.24	-0.16	-0.13	0.06		-0.36	-0.1	-0.25	-0.18
Cash And Equivalents	0.66	0.7	0.51	0.6	0.64	0.43	0.48	0.75	-0.24	0.07	0.58	0.28	0.72	0.63	-0.61	0.56	-0.41	0.65	0.76	0.76	-0.37	0.65	-0.36		0.78	0.92	0.6
Net Invested Capital	0.87	0.91	0.82	0.79	0.86	0.73	0.6	0.77	0.02	0.22	0.81	0.34	0.84	0.81	-0.65	0.79	-0.47	0.83	0.92	0.89	-0.49	0.67	-0.1	0.78		0.94	0.77
Net Working Capital	0.8	0.84	0.71	0.72	0.77	0.6	0.58	0.81	-0.12	0.16	0.74	0.33	0.83	0.75	-0.68	0.72	-0.49	0.82	0.89	0.86	-0.46	0.75	-0.25	0.92	0.94		0.69
Capital Stock	0.7	0.78	0.56	0.69	0.8	0.64	0.29	0.53	-0.1	0.01	0.61	0.3	0.51	0.64	-0.45	0.68	-0.17	0.87	0.68	0.91	-0.41	0.41	-0.18	0.6	0.77	0.69

Click cells to compare fundamentals

Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.

Competition

Predict Boston Scientific

Working Capital Over Time

Boston Capital Surpluse

Capital Surpluse

19.27 Billion

At this time, Boston Scientific's Capital Surpluse is fairly stable compared to the past year.

In accordance with the company's disclosures, Boston Scientific Corp has a Working Capital of 1.58 B. This is 271.43% higher than that of the Health Care Equipment & Supplies sector and 16.17% higher than that of the Health Care industry. The working capital for all United States stocks is 6.96% lower than that of the firm.

Boston Working Capital Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Boston Scientific's direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Boston Scientific could also be used in its relative valuation, which is a method of valuing Boston Scientific by comparing valuation metrics of similar companies.

Boston Scientific is currently under evaluation in working capital category among its peers.

Boston Scientific ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Boston Scientific's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Boston Scientific's managers, analysts, and investors.

Environmental

Governance

Social

Boston Fundamentals

	Return On Equity	0.0892
	Return On Asset	0.049
	Profit Margin	0.11 %
	Operating Margin	0.17 %
	Current Valuation	141.65 B
	Shares Outstanding	1.47 B
	Shares Owned By Insiders	0.17 %
	Shares Owned By Institutions	92.35 %
	Number Of Shares Shorted	12.91 M
	Price To Earning	107.05 X
	Price To Book	6.42 X
	Price To Sales	8.48 X
	Revenue	14.24 B
	Gross Profit	8.68 B
	EBITDA	3.45 B
	Net Income	1.59 B
	Cash And Equivalents	928 M
	Cash Per Share	0.24 X
	Total Debt	9.49 B
	Debt To Equity	0.51 %
	Current Ratio	1.45 X
	Book Value Per Share	14.05 X
	Cash Flow From Operations	2.5 B
	Short Ratio	1.91 X
	Earnings Per Share	1.21 X
	Price To Earnings To Growth	1.63 X
	Target Price	97.0
	Number Of Employees	48 K
	Beta	0.8
	Market Capitalization	134.86 B
	Total Asset	35.14 B
	Retained Earnings	819 M
	Working Capital	1.58 B
	Current Asset	1.21 B
	Current Liabilities	923 M
	Net Asset	35.14 B

About Boston Scientific Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Boston Scientific Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Boston Scientific using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Boston Scientific Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Boston Stock Analysis

When running Boston Scientific's price analysis, check to measure Boston Scientific's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Boston Scientific is operating at the current time. Most of Boston Scientific's value examination focuses on studying past and present price action to predict the probability of Boston Scientific's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Boston Scientific's price. Additionally, you may evaluate how the addition of Boston Scientific to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC